ClinicalTrials.gg
RecruitingNCT03510208Updated Jun 29, 2026

Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery

A Phase 1/2 interventional study of Near-Infrared Fluorescence Imaging and Panitumumab in Malignant Brain Neoplasm and Malignant Glioma, sponsored by Stanford University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by Stanford University · Phase 1/2, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started May 2018; still recruiting 8 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
46
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Brain Neoplasms by Stanford University — 4 open to participants now, 4 under way, none of them phase 3. Brain Neoplasms · Stanford University.

Planned enrollment
3rd of 10
46 · median 20
Started
2018
with 1 other
Phase 1/2
3 of 12
2 open now
Registered
7th of 12
by date

Among the 12 studies in Brain Neoplasms by Stanford University, this one is the 3rd largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2018, is one of 3 in phase 1/2, and was the 7th registered.

Brain Neoplasms

2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

4 of the 12 studies in Brain Neoplasms by Stanford University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 83 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Brain Neoplasms by Stanford University, or all of them as a file.
02

Study summary

The phase I/II trial studies the side effects and best dose of panitumumab-IRDye800 in diagnosing participants with malignant glioma who undergo surgery. Panitumumab-IRDye800 can attach to tumor cells and make them more visible using a special camera during surgery, which may help surgeons better distinguish tumor cells from normal brain tissue and identify small tumors that cannot be seen using current imaging methods.

Read the detailed description

PRIMARY OBJECTIVES:

I. Determine/verify the safety and pharmacokinetic profile of panitumumab conjugated to the optical dye IRDye800CW (panitumumab-IRDye800), as an imaging agent in patients undergoing surgery for malignant glioma.

SECONDARY OBJECTIVES:

I. Determine the efficacy of panitumumab IRDye800 in identifying malignant glioma compared to surrounding normal central nervous system tissue.

II. Determine whether a loading dose of panitumumab is necessary to achieve an effective tumor-to-background ratio.

III. Determine the optimal timing of the surgical procedure to maximize the tumor-to-background ratio.

OUTLINE: This is a phase I, dose escalation study of panitumumab-IRDye800 followed by a phase II study.

03

Conditions studied

  • Malignant Brain Neoplasm
  • Malignant Glioma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1) One of the following:

  1. Cohorts 1, 2, and 3: Participants with suspected or confirmed diagnosis of glioblastoma
  2. Cohort 4: Participants with suspected or confirmed diagnosis of vestibular schwannoma

    2.) Planned surgical removal of the tumor as part of standard of care. This may include participants postchemotherapy, post-radiation, and/or participants who have undergone diagnostic for their original diagnosis and are felt to be candidates for resection.

    3) Participant age ≥ 18 years.

    4) Participants or their designated advocates must be willing to and capable of providing and willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Received an drug within 30 days prior to first dose of Panitumumab-IRDye800.
  2. Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease as determined by PI; or unstable angina within 6 months prior to enrollment.
  3. History of infusion reactions to monoclonal antibody therapies
  4. Pregnant or breastfeeding.
  5. Evidence of prolongation on pretreatment (greater than 440 ms in males or greater than 460 ms in females).
  6. Any of the following lab values:

    1. count \< 75,000/mm3
    2. TSH ≥ 13 micro International Units/mL.
    3. Magnesium, potassium, or calcium \< each respective
    4. Serum creatinine > 1.5 times upper limit of normal
  7. Participants receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents.
  8. Participants with a history or evidence of interstitial pneumonitis or pulmonary fibrosis.
  9. Participants not deemed by PI to be appropriate candidates for optimal resection of tumor based on location, involvement of eloquent brain, satellite lesions, or other factors not specifically listed here.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
46 participants (estimated)

Study arms

  • Experimental
    Cohort 1 -50mg panitumumab-IRDye800

    A panitumumab-IRDye800 dose of 50mg (Cohort 1) with or without a 100 mg loading dose of unlabeled panitumumab will be injected 1 to 5 days before the planed standard of care surgery. Participants then undergo NIR imaging during standard of care surgery 1-5 days after receiving panitumumab-IRDye800.

    Procedure: Near-Infrared Fluorescence Imaging · Biological: Panitumumab · Drug: Panitumumab-IRDye800 · Device: POINPOINT-IR9000

  • Experimental
    Cohort 2 -100mg panitumumab-IRDye800

    A panitumumab-IRDye800 dose of 100mg (Cohort 2) with or without a 100 mg loading dose of unlabeled panitumumab will be injected 1 to 5 days before the planed standard of care surgery. Participants then undergo NIR imaging during standard of care surgery 1-5 days after receiving panitumumab-IRDye800.

    Procedure: Near-Infrared Fluorescence Imaging · Biological: Panitumumab · Drug: Panitumumab-IRDye800 · Device: POINPOINT-IR9000

  • Experimental
    Cohort 3 -100mg panitumumab-IRDye800

    Cohort 3 dose will be determined based on Cohort 1 and Cohort 2, with or without a 100 mg loading dose of unlabeled panitumumab will be injected 1 to 5 days before the planed standard of care surgery

    Procedure: Near-Infrared Fluorescence Imaging · Biological: Panitumumab · Drug: Panitumumab-IRDye800 · Device: POINPOINT-IR9000

  • Experimental
    Cohort 4

    Cohort 4 will enroll 24 participants with vestibular schwannomas at the optimal dose of 100mg, as determined by the research team based on data analysis from the first two cohorts.

    Procedure: Near-Infrared Fluorescence Imaging · Biological: Panitumumab · Drug: Panitumumab-IRDye800 · Device: POINPOINT-IR9000

Interventions

  • ProcedureNear-Infrared Fluorescence Imaging

    Undergo NIR imaging

    Also known as: NIR Fluorescence Imaging, NIR Optical Imaging

  • BiologicalPanitumumab

    Given IV

    Also known as: ABX-EGF, ABX-EGF Monoclonal Antibody, ABX-EGF, Clone E7.6.3, MoAb ABX-EGF, Monoclonal Antibody ABX-EGF, Vectibix

  • DrugPanitumumab-IRDye800

    Drug pages: PanitumumabStudies of PanitumumabPanitumumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · IRDye800Studies of IRDye800IRDye800 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given IV

    Also known as: Panitumumab IRDye 800, RDye800-Panitumumab Conjugate

  • DevicePOINPOINT-IR9000

    Intraoperative camera capable of exciting and detecting near infrared (NIR) dyes. Imaging will be performed on subjects during surgery and/or on ex-vivo resected tissues in the surgery suite ("back table").

06

What researchers measure

Primary outcomes

  1. Number of grade 2 or higher adverse events which have been determined to be clinically significant and definitely, probably, or possibly related to the study treatment, graded according to Common Terminology Criteria for Adverse Effects (CTCAE) v. 4.0

    Descriptive statistical analysis of subject disposition, baseline characteristics, exposure to study drug, and adverse events will be performed. Descriptive statistics for continuous data will include mean, standard deviation, median, minimum, maximum, and inter-quartile values. Frequencies and percentages will be used to summarize categorical data.

    Time frame: Up to 30 days

Secondary outcomes

  1. Tumor to background ratio (TBR)

    TBR is defined as the fluorescence intensity of tumor tissue compared to that or normal surrounding tissue as determined by ex vivo pathological imaging. Will be analyzed with the individual specimen as the unit of analysis using the Wilcoxon signed rank test.

    Time frame: 30 days from study treatment

  2. Panitumumab Loading Dose

    The fluorescence intensity of tissue obtained from patients undergoing surgery will be evaluated as an indicator of whether or not the loading dose of panitumumab is necessary to achieve an effective tumor-to-background ratio (TBR). The Fluorescence intensity of tissue will be assessed on the specimens collected on the day of surgery (Day 1-5 Post infusion), in group a vs group b, for Cohorts 1 and 2, in order to determine the tumor-to-background ratio (TBR). The outcome will be expressed as TBR by group and cohort. TBR will be reported as means +/- STD.

    Time frame: 30 days

  3. Optimal Timing of Surgical Procedure

    The fluorescence intensity of tissue collected at surgery will be measured 1 to 5 days after infusion, and the outcome will be assessed as highest daily mean tumor-to-background ratio (TBR), with standard deviation. The tissue analysis to obtain the outcome data will occur within 1 year from surgery.

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2018 (actual). Primary completion is estimated for Nov 2026, 102 months after the start.

Of 51 non-industry phase 1/2 interventional studies under Brain Neoplasms, half reached primary completion within 85 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 105. This study's planned 102 months is above that.

Counting every sponsor, half of 74 studies reached it within 85 months; a quarter within 49 and three quarters within 119.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2018
First posted
Apr 27, 2018
StartActual
May 16, 2018
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Jun 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03510208
Responsible party
Sponsor
First posted
Apr 27, 2018
Start date
May 16, 2018
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Jun 29, 2026

Study contacts

Sandra Torres
Contact
sandraet@stanford.edu
(650) 723-5281
Lindsay Moore, MD
principal investigator · Stanford University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Panitumumab · IRDye800

Start the discussion